Tumor Necrosis Factor Alpha (TNF-α) Inhibitors

NCT00073437 – A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement

Posted on October 8, 2019 by tsuperadmin -

NCT00060502 – A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer

Posted on January 16, 2019 by tsuperadmin -

NCT01453725 – A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Also Known as MK-8259-006-02)

Posted on October 23, 2018 by tsuperadmin -

NCT00036387 – A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug

Posted on September 10, 2018 by tsuperadmin -

NCT00207740 – A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma

Posted on August 6, 2018 by tsuperadmin -

NCT01962974 – A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

Posted on August 6, 2018 by tsuperadmin -

NCT01988961 – A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Posted on August 6, 2018 by tsuperadmin -

NCT01863771 – A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis

Posted on August 6, 2018 by tsuperadmin -

NCT01004432 – Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Posted on August 6, 2018 by tsuperadmin -

NCT02181673 – A Study of Golimumab in Participants With Active Psoriatic Arthritis

Posted on August 6, 2018 by tsuperadmin -